$40 million in financing to advance oral peptide drugs
22 July, 2015Protagonist Therapeutics has announced the closing of a $40 million Series C financing, the proceeds of which will be used to further the development of the company's oral peptide drug candidates.
Developing a platform for macrocyclic drugs
17 July, 2015Phylogica and the Institute for Molecular Bioscience have been awarded a $670,000 Linkage grant to develop a novel platform to generate macrocyclic peptide libraries.
Orthocell regenerates cartilage within joints
16 July, 2015An international research paper provides peer-reviewed support for Orthocell's new approach to the regeneration of damaged cartilage within joints.
AstraZeneca and Adelaide collaborate on drug discovery
13 July, 2015AstraZeneca's agreement with Adelaide Research and Innovation will provide an opportunity for researchers at the University of Adelaide to collaborate with industry-leading scientists to develop new medicines.
Grant to progress tendon fabrication project
09 July, 2015Orthocell has received an ARC grant of $430,000 to continue its investigation of tendon tissue and the development of novel therapies — such as the laboratory-fabricated tendon project announced by the company late last year.
Spinifex Pharmaceuticals sold to Novartis
08 July, 2015 by Susan WilliamsonAustralian biotech Spinifex Pharmaceuticals will be bought by global healthcare company Novartis for US$200 million.
3D-printed jaw implant a first
25 June, 2015Designed and made in Australia, a 3D-printed prosthetic jaw joint has been successfully used in reconstructive surgery.
Pooey pigs could be a thing of the past
18 June, 2015A second field trial of Anatara Lifesciences' non-antibiotic, natural therapy to prevent and treat diarrhoea in weaned pigs is being conducted in a large-scale commercial piggery in South East Queensland.
Commercialisation agreement for Canberra's synthetic catalyst
11 June, 2015A commercialisation deal for a new synthetic catalyst will help make the pharmaceutical manufacturing process more efficient, particularly in the production of ADD/ADHD drug Ritalin (methylphenidate).
Phosphagenics appoints consultant for promoting drug delivery tech
09 June, 2015Phosphagenics (ASX:POH) has engaged the services of Dr Steve Meller to assist the company in partnering its TPM (Targeted Penetration Matrix) drug delivery technology with large companies selling into the mass market.
Clinical Network Services is Australia's favourite CRO
09 June, 2015Clinical Network Services (CNS), an integrated service group focused on clinical product development, has been announced as Australia's favourite CRO for 2015 by ARCS Australia.
Partnership and Early Access Program for Antisense
01 June, 2015Melbourne biotech Antisense Therapeutics (ASX:ANP) has announced an Early Access Program (EAP) for its multiple sclerosis (MS) therapy ATL1102 in the European Union, as well as a partnership with a US-based company to develop its growth disorder treatment ATL1103.
Orphan designation for Huntington's candidate
01 June, 2015Prana Biotechnology has announced that the European Commission has approved orphan designation for its lead drug candidate, PBT2, for the treatment of Huntington's disease.
New Cochlear CEO appointed
26 May, 2015Chris Smith has been announced as the incoming CEO and president of Cochlear Limited (ASX:COH). He will become the company's deputy CEO from 1 July and relocate to Sydney to take up the CEO position as of 1 September.
GSK granted $1 million for advanced manufacturing project
21 May, 2015Healthcare company GSK Australia has received a $1 million grant through the federal government's Manufacturing Transition Programme. The funding will support GSK's advanced manufacturing expansion plans at its Boronia site in Melbourne's outer-eastern suburbs.
